Gonadotrophins: The future

Journal of Human Reproductive Sciences

Volumn 7, Issue 4, 2014, Pages 236-248

  Patil, Madhuri ^a  

^a Dr Patil s Fertility and Endoscopy Clinic   (India)

Author keywords

Assisted reproductive technology; corifollitropin alfa; gonadotrophins; ovulation induction; stimulation

Indexed keywords

CORIFOLLITROPIN ALFA; ESTRADIOL; FOLLITROPIN; GANIRELIX; GONADOTROPIN; LUTEINIZING HORMONE; RECOMBINANT CHORIONIC GONADOTROPIN; RECOMBINANT FOLLITROPIN; RECOMBINANT LUTEINIZING HORMONE;

ANTEPARTUM HEMORRHAGE; CELL FUNCTION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CRYOPRESERVATION; DRUG ADMINISTRATION ROUTE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HORMONE DETERMINATION; HUMAN; INFERTILITY THERAPY; INJECTION SITE REACTION; NONHUMAN; OOCYTE; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PELVIC PAIN; REVIEW; SINGLE DRUG DOSE;

EID: 84920263725     PISSN: 09741208     EISSN: 19984766     Source Type: Journal    
DOI: 10.4103/0974-1208.147490     Document Type: Review

References (51)

1. Fauser BC, Van Heusden AM. Manipulation of human ovarian function: Physiological concepts and clinical consequences. Endocr Rev 1997;18:71?106.
2. de Leeuw R, Mulders J, Voortman G, Rombout F, Damm J, Kloosterboer L. Structure?function relationship of recombinant follicle stimulating hormone (Puregon). Mol Hum Reprod 1996;2:361?9.
3. Howles CM. Genetic engineering of human FSH (Gonal?F). Hum Reprod Update 1996;2:172?91.
4. Olijve W, de Boer W, Mulders JW, van Wezenbeek PM. Molecular biology and biochemistry of human recombinant follicle stimulating hormone (Puregon). Mol Hum Reprod 1996;2:371?82.
5. Fares FA, Suganuma N, Nishimori K, LaPolt PS, Hsueh AJ, Boime I. Design of a long?acting follitropin agonist by fusing the C?terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit. Proc Natl Acad Sci USA 1992;89:4304?8.
6. Boime I, Ben?Menahem D. Glycoprotein hormone structure?function and analog design. Recent Prog Horm Res 1999;54:271?88.
7. Devroey P, Mannaerts B, Smitz J, Coelingh Bennink H, Van Steirteghem A. Clinical outcome of a pilot efficacy study on recombinant human follicle?stimulating hormone (Org 32489) combined with various gonadotrophin?releasing hormone agonist regimens. Hum Reprod 1994;9:1064?9.
8. Lunenfeld B. Historical perspectives in gonadotrophin therapy. Hum Reprod Update 2004;10:453?67.
9. Perlman S, van den Hazel B, Christiansen J, Gram?Nielsen S, Jeppesen CB, Andersen KV, et al. Glycosylation of an N?terminal extension prolongs the half?life and increases the in vivo activity of follicle stimulating hormone. J Clin Endocrinol Metab 2003;88:3227?35.
10. Low SC, Nunes SL, Bitonti AJ, Dumont JA. Oral and pulmonary delivery of FSH?Fc fusion proteins via neonatal Fc receptor?mediated transcytosis. Hum Reprod 2005;20:1805?13.
11. Sugahara T, Sato A, Kudo M, Ben?Menahem D, Pixley MR, Hsueh AJ, et al. Expression of biologically active fusion genes encoding the common alpha subunit and the follicle?stimulating hormone beta subunit. Role of a linker sequence. J Biol Chem 1996;271:10445?8.
12. Klein J, Lobel L, Pollak S, Ferin M, Xiao E, Sauer M, et al. Pharmacokinetics and pharmacodynamics of single?chain recombinant human follicle?stimulating hormone containing the human chorionic gonadotropin carboxyterminal peptide in the rhesus monkey. Fertil Steril 2002;77:1248?55.
13. Devroey P, Fauser BC, Platteau P, Beckers NG, Dhont M, Mannaerts BM. Induction of multiple follicular development by a single dose of long?acting recombinant follicle?Stimulating hormone (FSH?CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. J Clin Endocrinol Metab 2004;89:2062?70.
14. Corifollitropin Alfa Dose?finding Study Group. A randomized dose?response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. Hum Reprod 2008;23:2484?92.
15. Devroey P, Boostanfar R, Koper NP, Mannaerts BM, Ijzerman?Boon PC, Fauser BC, et al. A double?blind, non?inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod 2009;24:3063?72.
16. Fauser BC, Mannaerts BM, Devroey P, Leader A, Boime I, Baird DT. Advances in recombinant DNA technology: Corifollitropin alfa, a hybrid molecule with sustained follicle?stimulating activity and reduced injection frequency. Hum Reprod Update 2009;15:309?21.
17. Mahmoud Youssef MA, van Wely M, Aboulfoutouh I, El?Khyat W, van der Veen F, Al?Inany H. Is there a place for corifollitropin alfa in IVF/ICSI cycles? A systematic review and meta?analysis. Fertil Steril 2012;97:876?85.
18. Corifollitropin alfa Ensure Study Group. Corifollitropin alfa for ovarian stimulation in IVF: A randomized trial in lower?body?weight women. Reprod Biomed Online 2010;21:66?76.
19. Balen AH, Mulders AG, Fauser BC, Schoot BC, Renier MA, Devroey P, et al. Pharmacodynamics of a single low dose of long?acting recombinant follicle?stimulating hormone (FSH?carboxy terminal peptide, corifollitropin alfa) in women with World Health Organization group II anovulatory infertility. J Clin Endocrinol Metab 2004;89:6297?304.
20. Beckers NG, Macklon NS, Devroey P, Platteau P, Boerrigter PJ, Fauser BC. First live birth after ovarian stimulation using a chimeric long?acting human recombinant follicle?stimulating hormone (FSH) agonist (recFSH?CTP) for in vitro fertilization. Fertil Steril 2003;79:621?3.
21. de Greef R, Struijs M, de Haan A, Marintcheva?Petrova M, Mannaerts BM. Dose selection of Org 36286 (corifollitropin alfa) using pharmacokinetic and dynamic modeling and simulation. Hum Reprod 2007;22:i39. [Abstract O?099].
22. Pezzuto A, Ferrari B, Coppola F, Nardelli GB. LH supplementation in down?regulated women undergoing assisted reproduction with baseline low serum LH levels. Gynecol Endocrinol 2010;26:118?24.
23. Norman RJ, Zegers?Hochschild F, Salle BS, Elbers J, Heijnen E, Marintcheva?Petrova M, et al. Repeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: No concern for immunogenicity. Hum Reprod 2011;26:2200?8.
24. Duijkers IJ, Klipping C, Boerrigter PJ, Machielsen CS, De Bie JJ, Voortman G. Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long?acting recombinant FSH preparation (FSH?CTP) in healthy pituitary?suppressed females. Hum Reprod 2002;17:1987-93.
25. Voortman G, Mannaerts BM, Huisman JA. A dose proportionality study of s.c. and intramuscularly administered recombinant human FSH (Follistim/Puregon) in healthy female volunteers. Fertil Steril 2000;73:1187-93.
26. Groome NP, Illingworth PJ, O'Brien M, Pai R, Rodger FE, Mather JP, et al. Measurement of dimeric inhibin B throughout the human menstrual cycle. J Clin Endocrinol Metab 1996;81:1401?5.
27. Fauser BC, Alper MM, Ledger W, Schoolcraft WB, Zandvliet A, Mannaerts BM, et al. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reprod Biomed Online 2010;21:593?601.
28. Borm G, Mannaerts B. Treatment with the gonadotrophin?releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. Hum Reprod 2000;15:1490?8.
29. Fluker M, Grifo J, Leader A, Levy M, Meldrum D, Muasher SJ, et al. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril 2001;75:38?45.
30. Bouloux PM, Handelsman DJ, Jockenhövel F, Nieschlag E, Rabinovici J, Frasa WL, et al. First human exposure to FSH?CTP in hypogonadotrophic hypogonadal males. Hum Reprod 2001;16:1592?7.
31. La Marca A, D'Ippolito G. Ovarian response markers lead to appropriate and effective use of corifollitropin alpha in assisted reproduction. Reprod Biomed Online 2014;28:183?90.
32. Shoham Z. The clinical therapeutic window for luteinizing hormone in controlled ovarian stimulation. Fertil Steril 2002;77:1170?7.
33. le Cotonnec JY, Loumaye E, Porchet HC, Beltrami V, Munafo A. Pharmacokinetic and pharmacodynamic interactions between recombinant human luteinizing hormone and recombinant human follicle?stimulating hormone. Fertil Steril 1998;69:201?9.
34. Ruvolo G, Bosco L, Pane A, Morici G, Cittadini E, Roccheri MC. Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures. Fertil Steril 2007;87:542?6.
35. Klein NA, Battaglia DE, Fujimoto VY, Davis GS, Bremner WJ, Soules MR. Reproductive aging: Accelerated ovarian follicular development associated with a monotropic follicle?stimulating hormone rise in normal older women. J Clin Endocrinol Metab 1996;81:1038?45.
36. Bosch E, Labarta E, Crespo J, Simón C, Remohí J, Pellicer A. Impact of luteinizing hormone administration on gonadotropin?releasing hormone antagonist cycles: An age?adjusted analysis. Fertil Steril 2011;95:1031?6.
37. De Placido G, Alviggi C, Mollo A, Strina I, Ranieri A, Alviggi E, et al. Effects of recombinant LH (rLH) supplementation during controlled ovarian hyperstimulation (COH) in normogonadotrophic women with an initial inadequate response to recombinant FSH (rFSH) after pituitary downregulation. Clin Endocrinol (Oxf) 2004;60:637?43.
38. Weil S, Vendola K, Zhou J, Bondy CA. Androgen and follicle?stimulating hormone interactions in primate ovarian follicle development. J Clin Endocrinol Metab 1999;84:2951?6.
39. Westergaard LG, Laursen SB, Andersen CY. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod 2000;15:1003?8.
40. Ferraretti AP, Gianaroli L, Magli MC, D'angelo A, Farfalli V, Montanaro N. Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. Fertil Steril 2004;82:1521?6.
41. Kolibianakis EM, Kalogeropoulou L, Griesinger G, Papanikolaou EG, Papadimas J, Bontis J, et al. Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta?analysis. Hum Reprod Update 2007;13:445?52.
42. Hugues JN, Soussis J, Calderon I, Balasch J, Anderson RA, Romeu A, et al. Does the addition of recombinant LH in WHO group II anovulatory women over?responding to FSH treatment reduce the number of developing follicles? A dose?finding study. Hum Reprod 2005;20:629?35.
43. Papanikolaou EG, Verpoest W, Fatemi H, Tarlatzis B, Devroey P, Tournaye H. A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin?releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: A randomized prospective proof of concept study. Fertil Steril 2011;95:1174?7.
44. Pacchiarotti A, Sbracia M, Frega A, Selman H, Rinaldi L, Pacchiarotti A. Urinary hMG (Meropur) versus recombinant FSH plus recombinant LH (Pergoveris) in IVF: A multicenter, prospective, randomized controlled trial. Fertil Steril 2010;94:2467?9.
45. le Contonnec JY, Porchet HC, Beltrami V, Khan A, Toon S, Rowland M. Clinical pharmacology of recombinant human follicle?stimulating hormone. II. Single doses and steady state pharmacokinetics. Fertil Steril 1994;61:679?86.
46. Porchet HC, Le Cotonnec JY, Canali S, Zanolo G. Pharmacokinetics of recombinant human follicle stimulating hormone after intravenous, intramuscular, and subcutaneous administration in monkeys, and comparison with intravenous administration of urinary follicle stimulating hormone. Drug Metab Dispos 1993;21:144?50.
47. Weinbauer GF, Simoni M, Hutchison JS, Nieschlag E. Pharmacokinetics and pharmacodynamics of recombinant and urinary human FSH in the male monkey (Macaca fascicularis). J Endocrinol 1994;141:113?21.
48. Mannaerts BM. Novel FSH and LH agonists. In: Filicori M, editors. Proceedings of the Fourth World Congress on Ovulation Induction (Bologna, 27?29 May, 2004). Rome: Aracne Proceedings; 2005. p. 159?72.
49. van de Lagemaat R, Timmers CM, Kelder J, van Koppen C, Mosselman S, Hanssen RG. Induction of ovulation by a potent, orally active, low molecular weight agonist (Org 43553) of the luteinizing hormone receptor. Hum Reprod 2009;24:640?8.
50. Bachmann K, Pardoe D, White D. Scaling basic toxicokinetic parameters from rat to man. Environ Health Perspect 1996;104:400?7.
51. Hill MJ, Levens ED, Levy G, Ryan ME, Csokmay JM, DeCherney AH, et al. The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: A systematic review and meta?analysis. Fertil Steril 2012;97:1108?141.